Bristol Myers Squibb (BMS) has agreed to acquire its longtime cell therapy partner 2seventy bio in a deal valued at $286m. Announced after markets closed on 10 March, the $5-per-share offer ...
The $5-per-share purchase price represents an 88 ... Lynelle Hoch, president of BMS’ cell therapy organization, said in a statement to Fierce Pharma. The deal comes as a bargain for the Big ...
That represents a 78.5% premium to 2seventy’s ... which brings its cell therapy experience and manufacturing infrastructure. BMS and 2seventy share equally in the profits and losses from sales ...
Bristol Myers Squibb (BMS) has agreed to acquire its longtime cell therapy partner 2seventy bio in a deal valued at $286m. Announced after markets closed on 10 March, the $5-per-share offer represents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback